JPWO2021214277A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021214277A5
JPWO2021214277A5 JP2022564304A JP2022564304A JPWO2021214277A5 JP WO2021214277 A5 JPWO2021214277 A5 JP WO2021214277A5 JP 2022564304 A JP2022564304 A JP 2022564304A JP 2022564304 A JP2022564304 A JP 2022564304A JP WO2021214277 A5 JPWO2021214277 A5 JP WO2021214277A5
Authority
JP
Japan
Prior art keywords
seq
cdr
amino acid
acid sequence
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022564304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522417A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/060637 external-priority patent/WO2021214277A1/en
Publication of JP2023522417A publication Critical patent/JP2023522417A/ja
Publication of JPWO2021214277A5 publication Critical patent/JPWO2021214277A5/ja
Pending legal-status Critical Current

Links

JP2022564304A 2020-04-24 2021-04-23 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節 Pending JP2023522417A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20171356.7 2020-04-24
EP20171356 2020-04-24
PCT/EP2021/060637 WO2021214277A1 (en) 2020-04-24 2021-04-23 Enzyme and pathway modulation with sulfhydryl compounds and their derivatives

Publications (2)

Publication Number Publication Date
JP2023522417A JP2023522417A (ja) 2023-05-30
JPWO2021214277A5 true JPWO2021214277A5 (es) 2023-12-07

Family

ID=70464886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564304A Pending JP2023522417A (ja) 2020-04-24 2021-04-23 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節

Country Status (17)

Country Link
US (1) US20230265204A1 (es)
EP (1) EP4139349A1 (es)
JP (1) JP2023522417A (es)
KR (1) KR20230005172A (es)
CN (1) CN115427443A (es)
AR (1) AR121918A1 (es)
AU (1) AU2021258475A1 (es)
BR (1) BR112022021203A2 (es)
CA (1) CA3178472A1 (es)
CL (1) CL2022002885A1 (es)
CR (1) CR20220531A (es)
IL (1) IL296664A (es)
MX (1) MX2022013173A (es)
PE (1) PE20230078A1 (es)
TW (1) TW202206459A (es)
WO (1) WO2021214277A1 (es)
ZA (1) ZA202210643B (es)

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3334167A1 (de) 1983-09-21 1985-04-04 Siemens AG, 1000 Berlin und 8000 München Halbleiterdiode
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ES2201077T3 (es) 1993-05-28 2004-03-16 Baylor College Of Medicine Metodo y espectrometro de masas para la desorcion e ionizacion de analitos.
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999038194A1 (en) 1998-01-23 1999-07-29 Analytica Of Branford, Inc. Mass spectrometry from surfaces
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
JP4820055B2 (ja) * 2001-12-27 2011-11-24 グライコフィ, インコーポレイテッド 哺乳動物型糖質構造を操作するための方法
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
RS51318B (sr) 2002-12-16 2010-12-31 Genentech Inc. Varijante imunoglobulina i njihova upotreba
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CA2678963C (en) 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
PL2592148T3 (pl) 2007-10-12 2019-01-31 F. Hoffmann-La Roche Ag Ekspresja białka z wielu kwasów nukleinowych
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
ES2544569T3 (es) 2008-12-19 2015-09-01 Biogen International Neuroscience Gmbh Autoanticuerpos humanos anti alfa-sinucleina
KR20110013687A (ko) 2009-08-03 2011-02-10 삼성모바일디스플레이주식회사 유기전계발광표시장치 및 그의 구동방법
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
CN107586340B (zh) 2011-08-23 2022-01-21 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
PT3378535T (pt) 2011-10-28 2023-02-06 Prothena Biosciences Ltd Anticorpos humanizados que reconhecem a alfa-sinucleína
BR112014018561A8 (pt) 2012-01-27 2017-07-11 Neotope Biosciences Ltd Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
SG10202007189VA (en) 2013-11-21 2020-09-29 Hoffmann La Roche ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
DK3177643T3 (da) 2014-08-04 2019-07-15 Hoffmann La Roche Bispecifikke T-celle-aktiverende antigenbindende molekyler
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2018220099A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN110869391A (zh) * 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
US20220018851A1 (en) * 2018-08-09 2022-01-20 Hoffmann-La Roche Inc. Determination of parkinson's disease

Similar Documents

Publication Publication Date Title
DK3126383T3 (en) MODIFIED J-CHAIN
US8945870B2 (en) DNA encoding an anti-system ASC amino acid transporter 2 (ASCT2) antibody
WO2011155579A1 (ja) 抗Trop-2抗体
EP2138576A1 (en) Anti-claudin-4 antibody
JPWO2019175224A5 (es)
JPWO2019175223A5 (es)
JPWO2019175215A5 (es)
JPWO2019175226A5 (es)
JPWO2019175220A5 (es)
JPWO2019175216A5 (es)
JPWO2019175217A5 (es)
JPWO2019175222A5 (es)
JP2022541249A (ja) 特定の患者のがんを治療するための抗体の組み合わせ
IL295381A (en) bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
AU2019268959B2 (en) Use for preventing and treating myeloid-derived suppressor cell-related diseases
JPWO2021214277A5 (es)
JP2022122865A5 (es)
JPWO2019152705A5 (es)
AR126009A1 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
JPWO2020140084A5 (es)
JPWO2020210512A5 (es)
AR121918A1 (es) Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados
JPWO2021222578A5 (es)
JPWO2020183245A5 (es)
WO2021162098A1 (ja) Cd3に結合するバイスペシフィック抗体